Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation
Research output: Contribution to journal › Case report › Contributed › peer-review
Contributors
Details
Original language | English |
---|---|
Pages (from-to) | 687-694 |
Number of pages | 8 |
Journal | JCO precision oncology |
Volume | 5 |
Publication status | Published - Nov 2021 |
Peer-reviewed | Yes |
External IDs
Scopus | 85117736711 |
---|---|
Mendeley | 702ed7f2-03d4-3a82-a8ff-a7631ed2764e |